BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Gerber Scientific, Inc. Announces Fiscal 2007 Third Quarter Results


2/27/2007 10:46:25 AM

SOUTH WINDSOR, Conn., Feb. 27 /PRNewswire-FirstCall/ -- Gerber Scientific, Inc. today reported net income of $2.2 million for the third quarter of fiscal 2007, or $0.10 per diluted share, on revenue of $137.1 million, compared with a net loss of $0.1 million, or essentially break even on a diluted share basis, on revenue of $124.6 million for the third quarter of fiscal 2006. Foreign currency translation had the effect of increasing revenue by approximately $6.1 million in the third quarter of fiscal 2007, as compared with the third quarter of fiscal 2006.

For the nine months ended January 31, 2007, the Company reported net income of $7.9 million, or $0.34 per diluted share, on revenue of $419.7 million, compared with a net loss of $1.3 million, or $0.06 per diluted share, on revenue of $387.3 million for the nine months ended January 31, 2006. Foreign currency translation had the effect of increasing revenue by approximately $12.0 million for the nine months ended January 31, 2007, as compared with the nine months ended January 31, 2006. The Company's net loss for the nine months ended January 31, 2006 included a $2.5 million charge associated with the early extinguishment of the Company's former credit facility and a $2.3 million tax charge associated with the reversal of a deferred tax asset in the United Kingdom. These items negatively impacted the prior year-to-date diluted earnings per share by $0.18.

Marc T. Giles, President and Chief Executive Officer, commented: "Results for the third quarter reflected our continued focus on growth with revenue up 10.0 percent versus a year ago. In addition to favorable currency translation, this growth was largely a result of our initiatives in new products and in China and other Asian markets. Though our gross margin percentage declined from the prior year primarily related to business unit and product mix, our earnings per share for the third quarter grew to $0.10 per diluted share driven by higher revenue and internal focus on cost control."

For additional information please see our Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2007, which will be filed with the Securities and Exchange Commission.

About Gerber Scientific, Inc.

Gerber Scientific, Inc. (http://www.gerberscientific.com) is a leading international supplier of sophisticated automated manufacturing systems for the sign making and specialty graphics, apparel and flexible materials and ophthalmic lens processing industries. Headquartered in South Windsor, Connecticut, the Company operates through four businesses: Gerber Scientific Products, Spandex Ltd., Gerber Technology and Gerber Coburn.

Cautionary Note Concerning Factors That May Affect Future Results Statements contained in this news release regarding the Company's expected financial condition, results of operations, cash flows and product launches are forward-looking statements that involve risks and uncertainties. For information identifying other important economic, political, regulatory, legal, technological, competitive and other uncertainties, readers are referred to the Company's filings with the Securities and Exchange Commission, including but not limited to, the information included in Gerber Scientific's Annual Report on Form 10-K for the fiscal year ended April 30, 2006 under the headings "Business," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations - Cautionary Note Concerning Factors That May Influence Future Results," as well as information included in subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K, which outline certain important risks regarding the Company's forward- looking statements. These risks include, but are not limited to, delays in the Company's new product development and commercialization, intense competition in markets for each of the Company's operating segments, rapid technological advances, availability and cost of raw materials, volatility in foreign currency exchange rates and fluctuations in interest rates. The Company expressly disclaims any obligation to update any of these forward- looking statements, except as required by law. Actual future results or events may differ materially from these forward-looking statements.

GERBER SCIENTIFIC, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) In thousands, except per share data Quarter Ended Nine Months Ended January 31, January 31, 2007 2006 2007 2006 Revenue: Product sales $120,941 $109,324 $370,776 $341,117 Service sales 16,183 15,288 48,885 46,220 137,124 124,612 419,661 387,337 Costs and Expenses: Cost of products sold 86,881 78,233 264,401 242,303 Cost of services sold 10,242 9,120 29,922 28,069 Selling, general and administrative expenses 29,863 28,427 92,216 87,310 Research and development 6,050 5,959 18,193 18,789 Restructuring charges --- --- --- (231) 133,036 121,739 404,732 376,240 Operating income 4,088 2,873 14,929 11,097 Other income (expense), net (145) (754) (25) (1,437) Loss on early extinguishment of debt --- --- --- (2,483) Interest expense (965) (862) (2,713) (3,818) Income before income taxes 2,978 1,257 12,191 3,359 Income tax expense 748 1,349 4,248 4,658 Net income (loss) $2,230 $(92) $7,943 $(1,299) Earnings (Loss) per share of common stock: Basic $0.10 $0.00 $0.35 $(0.06) Diluted $0.10 $0.00 $0.34 $(0.06) Weighted average shares outstanding: Basic 23,012 22,466 22,828 22,371 Diluted 23,398 22,466 23,258 22,371 GERBER SCIENTIFIC, INC. AND SUBSIDIARIES CONSOLIDATED SUMMARY BALANCE SHEETS (Unaudited) In thousands January 31, April 30, 2007 2006 Assets Current Assets: Cash and cash equivalents $4,911 $14,145 Accounts receivable, net 92,620 92,422 Inventories 63,630 53,794 Prepaid expenses and other current assets 16,044 16,718 Total current assets 177,205 177,079 Property, plant and equipment, net 36,692 38,366 Goodwill 54,060 51,554 Deferred income taxes 32,009 27,696 Other assets 15,754 15,785 Total assets $315,720 $310,480 Liabilities and Shareholders' Equity Current Liabilities: Current portion of long-term debt $1,280 $284 Accounts payable 42,292 53,886 Accrued and other liabilities 55,165 57,248 Total current liabilities 98,737 111,418 Long-term debt 36,661 36,836 Other long-term liabilities 37,691 36,610 Shareholders' equity 142,631 125,616 Total liabilities and shareholders' equity $315,720 $310,480

Gerber Scientific, Inc.

CONTACT: Jay Zager, +1-860-644-1551



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->